PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase 2
Scott Z. Fields, MD, Bayer Pharmaceuticals explains PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase 2 at ASCO 2018
Author: Annual-Meeting
Added: 06/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Lymphoma